Credit Suisse’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $8.32M | Buy |
1,548,826
+18,918
| +1% | +$85.7K | 0.01% | 1012 |
|
|
2023
Q4 | $7.68M | Sell |
1,529,908
-4,229
| -0.3% | -$13.3K | 0.01% | 1076 |
|
|
2023
Q3 | $2.59M | Buy |
1,534,137
+517,643
| +51% | +$1.04M | ﹤0.01% | 1664 |
|
|
2023
Q2 | $2.83M | Buy |
1,016,494
+126,795
| +14% | +$359K | ﹤0.01% | 1696 |
|
|
2023
Q1 | $1.62M | Buy |
889,699
+199,965
| +29% | +$622K | ﹤0.01% | 2004 |
|
|
2022
Q4 | $3.5M | Sell |
689,734
-8,318
| -1% | -$45.7K | ﹤0.01% | 1543 |
|
|
2022
Q3 | $3.47M | Buy |
698,052
+9,578
| +1% | +$43.6K | ﹤0.01% | 1480 |
|
|
2022
Q2 | $2.56M | Buy |
688,474
+230,999
| +50% | +$928K | ﹤0.01% | 1738 |
|
|
2022
Q1 | $2.57M | Buy |
457,475
+26,721
| +6% | +$164K | ﹤0.01% | 1914 |
|
|
2021
Q4 | $2.62M | Buy |
430,754
+39,093
| +10% | +$294K | ﹤0.01% | 2575 |
|
|
2021
Q3 | $3.81M | Buy |
391,661
+213,636
| +120% | +$2.35M | ﹤0.01% | 2278 |
|
|
2021
Q2 | $2.54M | Sell |
178,025
-4,045
| -2% | -$66.8K | ﹤0.01% | 2668 |
|
|
2021
Q1 | $4.32M | Buy |
182,070
+20,487
| +13% | +$531K | ﹤0.01% | 2195 |
|
|
2020
Q4 | $2.15M | Buy |
161,583
+126,192
| +357% | +$1.21M | ﹤0.01% | 2763 |
|
|
2020
Q3 | $246K | Buy |
+35,391
| New | +$353K | ﹤0.01% | 3754 |
|
|
2020
Q2 | – | Sell |
-34,203
| Closed | -$99K | – | 4049 |
|
|
2020
Q1 | $99K | Sell |
34,203
-92,406
| -73% | -$463K | ﹤0.01% | 3822 |
|
|
2019
Q4 | $480K | Buy |
+126,609
| New | +$215K | ﹤0.01% | 3594 |
|
|
2018
Q3 | – | Sell |
-13,323
| Closed | -$41K | – | 3872 |
|
|
2018
Q2 | $41K | Sell |
13,323
-8,360
| -39% | -$31K | ﹤0.01% | 3918 |
|
|
2018
Q1 | $84K | Buy |
21,683
+8,274
| +62% | +$36.3K | ﹤0.01% | 3826 |
|
|
2017
Q4 | $60K | Sell |
13,409
-12,502
| -48% | -$59.2K | ﹤0.01% | 3899 |
|
|
2017
Q3 | $142K | Buy |
25,911
+6,740
| +35% | +$41.5K | ﹤0.01% | 4017 |
|
|
2017
Q2 | $145K | Buy |
19,171
+3,939
| +26% | +$17K | ﹤0.01% | 3680 |
|
|
2017
Q1 | $54K | Sell |
15,232
-9,488
| -38% | -$46.9K | ﹤0.01% | 3742 |
|
|
2016
Q4 | $142K | Sell |
24,720
-1,462
| -6% | -$9.75K | ﹤0.01% | 3893 |
|
|
2016
Q3 | $204K | Sell |
26,182
-14,165
| -35% | -$106K | ﹤0.01% | 3808 |
|
|
2016
Q2 | $250K | Buy |
40,347
+24,825
| +160% | +$193K | ﹤0.01% | 3770 |
|
|
2016
Q1 | $127K | Buy |
15,522
+1,900
| +14% | +$17.9K | ﹤0.01% | 3784 |
|
|
2015
Q4 | $236K | Buy |
13,622
+2,667
| +24% | +$39.6K | ﹤0.01% | 3812 |
|
|
2015
Q3 | $125K | Buy |
+10,955
| New | +$239K | ﹤0.01% | 4069 |
|
Other funds holding IBRX
Credit Suisse's IBRX Position: Q1 2024 in Review
Credit Suisse increased its ImmunityBio (IBRX) stake by 1.2% in Q1 2024, buying an estimated $85.7K and bringing the position to 1,548,826 shares worth $8.32M. The position accounts for 0.01% of the portfolio, ranked #1012.
Credit Suisse first reported a position in IBRX in Q3 2015 and has held it in 29 quarters since. 165 funds tracked by Wall St. Rank hold IBRX as of Q1 2024.
- Credit Suisse held 1,548,826 shares of ImmunityBio worth $8.32M as of Q1 2024.
- Credit Suisse bought 18,918 ImmunityBio shares in Q1 2024, an estimated $85.7K.
- ImmunityBio made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1012 holding.
- Credit Suisse first reported a position in ImmunityBio in Q3 2015 and has held it in 29 quarters since.
- 165 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.